Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-piperidinecarboxylic Acid, 1-((2s)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 2,2'-(1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene((1r)-3-(3,4-dimethoxyphenyl)propylidene))) Ester, (2s,2's)-
2. Ap 1903 Reagent
3. Ap1903
1. Ap1903
2. 195514-63-7
3. Ap-1903
4. Rimiducid [inn]
5. Ap 1903
6. H564l1w5j2
7. [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate
8. (1r,1'r)-((((ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl) (2s,2's)-bis(1-((s)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate)
9. 2-piperidinecarboxylic Acid, 1-((2s)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 2,2'-(1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene((1r)-3-(3,4-dimethoxyphenyl)propylidene))) Ester, (2s,2's)-
10. Unii-h564l1w5j2
11. Ap 1903 Reagent
12. Rimiducid (usan/inn)
13. Rimiducid [usan:inn]
14. Rimiducid [usan]
15. Rimiducid (ap1903)
16. Ap 1903new
17. Rimiducid [who-dd]
18. Chembl269259
19. Schembl10111062
20. Dtxsid80173226
21. Ex-a1711
22. Vha51463
23. Ap1903ap1903
24. S9726
25. Cs-3162
26. Db04974
27. Ac-35487
28. Hy-16046
29. D11195
30. A919658
31. Q27279658
32. (1r,1'r)-((((ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl)(2s,2's)-bis(1-((s)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate)
33. 2-piperidinecarboxylic Acid, 1-(1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) Ester, (2s-(1(r*),2r*(s*(s*(1(r*),2r*)))))-
| Molecular Weight | 1411.6 g/mol |
|---|---|
| Molecular Formula | C78H98N4O20 |
| XLogP3 | 11.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 20 |
| Rotatable Bond Count | 39 |
| Exact Mass | 1410.67744153 g/mol |
| Monoisotopic Mass | 1410.67744153 g/mol |
| Topological Polar Surface Area | 262 Ų |
| Heavy Atom Count | 102 |
| Formal Charge | 0 |
| Complexity | 2330 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in bone marrow transplant and graft versus host disease.
Treatment of graft versus host disease
Rimiducis is used to activate inducible caspase-9 produced by a modified gene included in some CAR T-cell therapies. This activation produces rapid induction of apoptosis in activated modified T-cells and resolution of the signs and symptoms of graft versus host disease within 24 hours.
Rimiducid binds to a drug binding domain derived from human FK506-binding protein which is present on a modified form of inducible caspase-9. This binding results in dimerization and subsequent activation of caspase-9. This system was designed to function as a "safety switch" in CAR T-cell therapy used in hematological cancers. Retroviral vectors used in production of these modified cells preferentially integrate this gene nearby promoters associated with T-cell activation. This results in higher expression of the modified inducible caspase-9 product in activated T-cells. In practice, this allows for specific targeting of these active T-cells by rimiducid which results in a decrease in circulating cell numbers of over 90% in the setting of graft versus host disease. This specificity spares non-alloreactive T-cells and allows for successful reconstitution of the transplanted immune system from these cells.[24753538] Additionally, these non-alloreactive cells retain their sensitivity to rimiducid.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Rimiducid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rimiducid, including repackagers and relabelers. The FDA regulates Rimiducid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rimiducid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rimiducid supplier is an individual or a company that provides Rimiducid active pharmaceutical ingredient (API) or Rimiducid finished formulations upon request. The Rimiducid suppliers may include Rimiducid API manufacturers, exporters, distributors and traders.
click here to find a list of Rimiducid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rimiducid DMF (Drug Master File) is a document detailing the whole manufacturing process of Rimiducid active pharmaceutical ingredient (API) in detail. Different forms of Rimiducid DMFs exist exist since differing nations have different regulations, such as Rimiducid USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rimiducid DMF submitted to regulatory agencies in the US is known as a USDMF. Rimiducid USDMF includes data on Rimiducid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rimiducid USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rimiducid suppliers with USDMF on PharmaCompass.
Rimiducid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rimiducid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rimiducid GMP manufacturer or Rimiducid GMP API supplier for your needs.
A Rimiducid CoA (Certificate of Analysis) is a formal document that attests to Rimiducid's compliance with Rimiducid specifications and serves as a tool for batch-level quality control.
Rimiducid CoA mostly includes findings from lab analyses of a specific batch. For each Rimiducid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rimiducid may be tested according to a variety of international standards, such as European Pharmacopoeia (Rimiducid EP), Rimiducid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rimiducid USP).
LOOKING FOR A SUPPLIER?
